Integrative Oncology Therapy Research Association
Versione italiana
Subscribe Our Newsletter

Your Name (requested)

Your email (requested)

I accept the Privacy Policy

Watch Us on YouTube
Find Us On Facebook
External Links

Panitumumab (ABX-EGF)

It is a monoclonal antibody with the same mechanism of action and the same indications of cetuximab.
The only difference is that it is fully humanized and therefore presumibly with a better tolerance profile. It is not currently on the market and then it is administered as part of study protocols. It is produced by the pharmaceutical company AMGEN.

Leave a Reply

Your email address will not be published. Required fields are marked *